Glibenclamide inhibits the activation of NLRP3 inflammasome and protects against inflammation and tissue damage in many inflammatory diseases, including bronchopulmonary dysplasia (Liao et al., 2015), allergic asthma (Cui et al., 2015), acute pancreatitis (York, Castellanos, Cabay, & Fantuzzi, 2014), sepsis (Koh et al., 2011), and atherosclerosis (Ling et al., 2013). Here, NLRP3 is linked to acute pancreatitis.